Home / Combinations / Thymosin Alpha-1 + LL-37
CombinationRecoveryEmerging evidence
Thymosin Alpha-1 + LL-37
Immune Support
A broad-spectrum immune support stack combining thymosin alpha-1's T-cell maturation and adaptive immune enhancement with LL-37's antimicrobial peptide activity and innate immune modulation. Thymosin alpha-1 is clinically used to restore immune competence in immunocompromised patients by promoting dendritic cell and NK cell activity, while LL-37 provides direct antimicrobial action and regulates inflammatory signalling. The stack targets both adaptive and innate arms of immunity through complementary mechanisms.
Stack components
Thymosin Alpha-1Compound 01
LL-37Compound 02
2
Compounds
3
Sources on file
19
Providers carry all
Mechanism
What each compound is researched for on its own. Nothing here describes an interaction between them.
Compound 01
Thymosin Alpha-1
Restores and amplifies adaptive immune function by promoting T-cell maturation, dendritic cell activity, and NK cell output; clinically validated for immune reconstitution in immunocompromised patients.
Compound 02
LL-37
Provides innate immune reinforcement through direct antimicrobial activity against bacteria, viruses, and fungi while modulating the inflammatory response to prevent immune over-activation.
Composition
2 compounds · 1 research area
Stated as recorded. This page describes each compound separately and makes no claim that they act together.
Safety notes
Thymosin Alpha-1 is approved in multiple countries for viral hepatitis and immune deficiencies but is not FDA-approved in the United States. LL-37 is an endogenous antimicrobial peptide; synthetic injectable LL-37 is a research compound with limited human clinical data. Both agents modulate immune function — use in individuals with autoimmune conditions, organ transplants, or on immunosuppressive therapy requires medical supervision. No formal combination safety data exists.
Author-written. Not derived from any compound field, and not covered by the profile-integrity audit that gates the peptide pages.
Research references3 sources
Strong
History of the discovery and clinical development of thymosin alpha1
Expert Opin Biol Ther 2009
Strong
Thymosin alpha 1 reduces the mortality of severe COVID-19 by restoration of lymphocytopenia
Int Immunopharmacol 2020
Strong
Cathelicidins, multifunctional peptides of the innate immunity
J Leukoc Biol 2004
Related combinations3 share an area
Anti-Aging · Recovery
Thymalin + Epithalon: Immune-Longevity Protocol
Thymalin+Epithalon
Muscle Growth · Fat Loss · Recovery
CJC-1295 + Ipamorelin + GHRP-6: GH Secretagogue Max
CJC-1295+Ipamorelin+GHRP-6
Muscle Growth · Fat Loss · Recovery · Anti-Aging
CJC-1295 + Ipamorelin: GH Optimization
CJC-1295+Ipamorelin
Educational use only
PeptideBase documents what compounds are researched together and what evidence exists for each one separately. It does not provide medical advice, diagnosis, treatment, prescribing guidance or dosing instructions. Last reviewed 19 Apr 2026.
PeptideBase documents what compounds are researched together and what evidence exists for each one separately. It does not provide medical advice, diagnosis, treatment, prescribing guidance or dosing instructions. Last reviewed 19 Apr 2026.